bioRxiv Science⌕ Search

bioRxiv · 10.64898/2026.09.12.751167

TRACEDD: A Tool-grounded Reasoning and Agentic Coordination for Explainable Drug Design

Abstract

Drug discovery depends on coordinated decisions across target validation, structure analysis, molecular design, developability assessment and synthetic feasibility, but current computational methods often operate as disconnected tools. Here, we introduce TRACEDD (Tool-grounded Reasoning and Agentic Coordination for Explainable Drug Design), a framework that makes three primary contributions: (1) It establishes a 'tool-first' multi agentic architecture where LLMs orchestrate validated computational tools rather than replace them, ensuring scientific rigor. (2) It implements a multi-agent system that mirrors expert discovery teams, enabling transparent and traceable decision-making through a Reason-Act-Observe loop. (3) It demonstrates an end-to-end workflow, from target validation to synthesis planning, that adaptively handles real-world data variability, such as the absence of experimental structures. The framework decomposes discovery into specialized agents for target validation, druggability assessment, molecular generation, lead optimization, ADMET evaluation, literature evidence integration and retrosynthesis, all operating through a Reason Act Observe workflow. Using JAK2 as a representative case, we show that the system can retrieve experimental protein structures, invoke AlphaFold when structures are unavailable, identify druggable pockets and perform de novo molecular generation. Known JAK2 inhibitors are used to define design hypotheses and guide reinforcement learning-based molecular generation, with docking scores/predicted pIC50 and other physicochemical/ADMET properties serving as reward and prioritization signals. The framework demonstrates a tool-first, reasoning-driven approach in which each major decision is linked to explicit tool invocation, intermediate evidence. By combining agentic orchestration with domain-specific computational tools, the system supports transparent, adaptable and human-verifiable molecular design workflows, providing a foundation for more reliable AI-assisted drug discovery.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Vangala, S. R., Kasturi, V. V., Bung, N., Roy, A.. 2026-09-18. TRACEDD: A Tool-grounded Reasoning and Agentic Coordination for Explainable Drug Design. https://doi.org/10.64898/2026.09.12.751167

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Senescence-associated KRAS upregulation in peripheral T cells links to premature coronary artery disease

Aims: Premature coronary artery disease (PCAD) lacks specific molecular drivers, and the role of immunosenescence is unclear. We investigated whether aging-related gene dysregulation in T cells contributes to PCAD. Methods: We combined bulk transcriptomics of PBMCs from 12 PCAD patients and 21 controls, single-cell RNA sequencing of PBMCs and human atherosclerotic plaques, weighted gene co-expression network analysis, gene perturbation network analysis, and molecular docking. Results: KRAS was identified as a hub gene intersecting PCAD-associated genes and aging-related genes. Single-cell analysis showed KRAS upregulation predominantly in effector CD8+ T cells, which exhibited the highest senescence scores that were further elevated in disease. Network perturbation of KRAS strongly impacted the cell killing pathway. KRAS-high effector CD8+ T cells were detected in coronary and carotid plaques, displaying enhanced cytotoxicity, exhaustion, and senescence features. Additionally, a candidate small molecule was computationally predicted to bind inactive KRAS. Conclusions: Elevated KRAS expression in senescent, cytotoxic CD8+ T cells is associated with PCAD, bridging immunosenescence and premature atherosclerosis. This finding provides a novel biomarker candidate and potential therapeutic entry point, awaiting further functional validation.

bioinformatics↗

Targeted finetuning enables co-folding models to learn ligand-induced protein conformational states

Advances in protein structure prediction have enabled all-atom protein-ligand co-folding models that predict bound conformations directly from sequence and small-molecule structure. However, these models often fail to generalize to novel binding sites or alternative protein conformational states, limiting their utility for chemical biology and drug discovery. Here we show this limitation reflects training data bias rather than architectural constraints and can be overcome through targeted finetuning. Using ten previously unseen X-ray structures of Werner (WRN) helicase from a drug discovery program, we finetune Boltz-1 to learn both an allosteric binding site and a large conformational change locking the enzyme in an inactive state, while preserving accuracy on the ATP-bound state. The finetuned model generalizes to different chemical series and transfers the conformational logic across RecQ-family helicases in a binding-site sequence-dependent manner. This approach provides a blueprint for adapting foundation models as new structural and mechanistic data emerge, enabling co-folding networks to capture ligand-induced conformational switches and binding poses absent from their training data but central to biological regulation and therapeutic intervention.

bioinformatics↗

Benchmarking single-cell foundation models for aging biology

Single cell foundation models (scFMs) provide representations of cellular states, but their utility across biological questions in aging research remains unclear. We established a benchmark of cellular representations for aging research, evaluating ten general-purpose scFMs, three aging-specific models and conventional methods across five biological questions using more than 2.5 million single cell transcriptomes. Using frozen pretrained representations, Geneformer performed best among scFMs for chronological age prediction and age pseudotime concordance, although 2,000 highly variable genes achieved higher mean performance. Several scFMs captured positive molecular age shifts across three disease contexts, consistent with reported aging-associated changes. SCimilarity performed well for rare cellular state identification across out-of-distribution datasets, exceeding aging specific models and conventional baselines. At the gene level, scGPT showed the highest recovery of reference TF target interactions, including aging-related regulatory hubs. Overall, scFMs supported diverse aging analyses, but performance depended on the biological question, highlighting their utility for rare cellular state identification and regulatory analysis.

bioinformatics↗